Omega Therapeutics IPO Presentation Deck

Specificity Highly specific targeting of EpiZips within IGDs and disease-specific cellular modulation with OECS Significance (log scale) 2 Ⓒ2021 Omega Therapeutics, Inc. 5 6 Highly specific targeting of EpiZip using OEC Chromosomes 10 11 12 13 14 15 16 17 HEK293.17.pX.Y.Z.817 -23,000 CTCF sites at natural level of flux remained untouched by Controller 19 20 21 22 -Targeted single CTCF binding of an IGD on chromosome 17 18 17

View entire presentation